Gain Therapeutics Inc at Jefferies Healthcare Conference Transcript
Good afternoon, and welcome to the Jefferies Global Healthcare Conference. My name is Jamie Cohen with Jefferies Investment Banking. And it is my great pleasure to welcome Matthias Alder from Gain Therapeutics.
Thank you, Jamie. And thanks to Jefferies for organizing this conference and giving us the opportunity to present the exciting story that we have at Gain Therapeutics. So Gain is a computational drug discovery company that is leading the discovery and development of allosteric small molecule therapies. That's a very compact, condensed statement and I'll unpack that for you over the next 20 minutes or so.
We're a public publicly-traded company. So I will be making forward-looking statements. So consider risk factors in our SEC filings before making investment decisions.
Gain has essentially three areas that drive value for the company and our stakeholders. The first area is the SEE-Tx drug discovery platform. It's AI and physics-based. I'll go a bit more in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |